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Editorial on the Research Topic
B Cells in Inflammatory and Neurodegenerative Diseases of the Central Nervous System
In recent years, the role of B cells in conditions affecting the central nervous system
(CNS) has substantially expanded our perspectives on mechanisms of neuroinflammation and
neurodegeneration. The success of B cell-depleting therapies (BCDT) in patients with diseases
such as neuromyelitis optica and multiple sclerosis (MS) has underscored the role of B cells
in both cellular and humoral-mediated CNS conditions. This Research Topic aimed to provide
a comprehensive overview of the functions of B cells in the CNS during homeostasis and in
the presence of inflammatory and/or neurodegenerative diseases. Ultimately, the contributions
received for this Research Topic covered three main areas (1) antibodies, (2) B cells functions, and
(3) therapies, mainly focusing on MS.
Two contributions are focused on the pathogenic role of antibodies. The presence of
persistent oligoclonal bands (OCBs) and IgG deposition in demyelinating plaques are essential
features of MS pathology. However, their role remains controversial. In their review, Yu et al.
hypothesized that circulating IgG1 and IgG3 diffuse across a transiently damaged blood-brain
barrier (BBB), contributing to the total intrathecal IgGs and increasing the risk of antibodies-
mediated cytotoxicity to CNS cells. However, MS still does not meet the full definition of
autoimmune disease, and more studies are needed to clarify the pathological role of antibodies
in MS.
Understanding the immunopathogenic functions of antibodies is relevant in a wide range
of CNS conditions other than MS. In their original research article, Hang et al. focus on the
anti-leucine-rich glioma-inactivated 1 antibody (anti-LGI1) encephalitis, a common autoimmune
encephalitis characterized by progressive cognitive impairment. By analyzing the clinical outcome
of 21 patients, the authors conclude that considerable antibodies-mediated damage is seen in
patients early in the disease, and early and long-term effective immunotherapy can obtain a better
cognitive functional prognosis.
Five additional contributions in this Research Topic are focused on the role and function of
B cells in CNS conditions. In their review, Chunder et al. discuss the involvement of B cells in
two different neuroinflammatory scenarios by drawing parallels between MS and virus-induced
neuroinflammation. Both conditions show similar signatures for B cell migration, retention, and
regulation in the CNS. Thus, the authors conclude that the basics of B cell biology remain the
same independently of the trigger of neuroinflammation, showing a balance between protective
and pathogenic functions.
As the nature of the B cell response differs considerably between the stages of the disease,
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Holloman et al. explore the mechanisms by which B cells
contribute to disease progression in primary-progressive MS
(PPMS), specifically focusing on cytokine production, antigen
presentation, and antibodies synthesis. Authors draw their
conclusions based on the analysis of clinical trial data
highlighting the existence of a subset of patients with PPMS. The
latter have active inflammation contributing to their progressive
disability and benefit from BCDTs such as Ocrelizumab.
Altogether, the data indicate that BCDTs likely reduce disease
progression in PPMS by reducing B cell-mediated inflammation.
Two more review articles focus on the function of specific
B cell phenotypes in MS. In their review, Ran et al. unravel
the role of regulatory B cells (Breg) and their diversification in
demyelinating diseases. An increasing number of studies have
confirmed that Breg improveMS. According to the inflammatory
microenvironment and the interactions with surrounding cells,
Breg can indeed be activated and differentiate into subgroups
of cells with beneficial rather than pathogenic functions.
Concurrently, DiSano et al. discuss the roles of memory B
cells (Bmem), both within the periphery and inside the CNS
compartment. Bmem are rising as a critical B cell phenotype
in MS due to their antigen experience and rapid response to
stimulation. Bmem display diverse effector functions, including
antigen presentation to CD4+ T cells and precursor to antibody-
secreting cells (ASC). On this same line of thought, Negron et
al. discuss the evidence supporting the interconnectedness of
CD4+ T cells, particularly follicular T helper (TFH) cells and
B cells. T cell-dependent B cell responses originate and take
shape in germinal centers (GCs), specialized microenvironments
that regulate B cell activation and subsequent differentiation into
ASCs or Bmem, a process for which TFH cells are indispensable.
GCs represent a critical site of B cell tolerance, and their
dysregulation has been implicated in the pathogenesis of several
autoimmune diseases, including MS.
Finally, three contributions to this Research Topic focus on
different aspects of MS treatment, two specifically discussing
BCDTs. Roach and Cross critically review the results of
past and ongoing clinical trials of anti-CD20 monoclonal
antibodies (mAb) with lytic effects on B cells in MS: Rituximab,
Ocrelizumab, and Ofatumumab. The authors review nicely and
succinctly also safety profiles, the potential mechanism of action,
and alternatives to interfere with B cell function, e.g., anti-
CD19 mAb. Complementary to this contribution is the original
work by Sempere et al., reporting their real-world experience
in a retrospective analysis of 70MS patients, both relapsing and
progressive, treated with Ocrelizumab. Authors report clinical
and MRI results, showing that 94% of relapsing patients achieved
no evidence of disease activity (NEDA). Despite the overall low
number of patients included, this study confirms the effectiveness
of BCDTs in the treatment of MS.
The last article on this topic is shifting gear by proposing a
new algorithm for progressive multifocal leukoencephalopathy
(PML) risk stratification in patients treated with Natalizumab, an
anti-α4 integrin mAb interfering with lymphocyte, both T and B
cells, migration through the BBB. In this study by Toboso et al.,
1,240 people with MS treated with Natalizumab were recruited
in 36 European Hospitals to evaluate patients’ clinical and
demographic characteristics as predictors of PML occurrence.
Thirty-five patients developed PML and based on the analysis of
B cell-related parameters like anti-lipid specific IgM OCBs and
anti-JC virus antibodies, besides disease activity and age, authors
established a new algorithm as a PML risk stratification tool for
individual patients.
In conclusion, this Research Topic highlights the involvement
of B cells in neuroinflammatory diseases. It discusses the evidence
supporting B cells’ pathogenic immunomodulatory functions in
neurological disorders, particularly B cell-directed therapies.
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